Publication:
Growth Arrest-Specific 6 and Cardiometabolic Risk Factors in Patients with Psoriasis

Simple item page
dc.contributor.authorSEÇKİN GENÇOSMANOĞLU, DİLEK
dc.contributor.authorsSunbul, Murat; Cagman, Zeynep; Gerin, Fethullah; Ozgen, Zuleyha; Durmus, Erdal; Seckin, Dilek; Ahmad, Sarfraz; Uras, Fikriye; Agirbasli, Mehmet
dc.date.accessioned2022-03-14T11:08:16Z
dc.date.available2022-03-14T11:08:16Z
dc.date.issued2015-04
dc.description.abstractObjectivesAn increased risk for cardiovascular disease with psoriasis has been reported. Growth Arrest-Specific 6 (GAS6) amplifies pro-inflammatory endothelial cell activation via TAM receptors. However, it also inhibits inflammation by multiple mechanisms including phagocytosis. The objective of this study was to investigate whether plasma GAS6 levels are associated with conventional cardiometabolic (CM) risk factors in patients with psoriasis. MethodsForty patients diagnosed with psoriasis (22 male, mean age: 43.313.8years) and 40 age-/sex-matched healthy controls (22 male, mean age: 39.38.9years) were included in the study. CM risk factors (hypertension, hyperlipidemia, diabetes mellitus, and cigarette smoking) were identified. GAS6 levels were measured by ELISA. ResultsThere were no significant differences between the plasma GAS6 levels of patients with psoriasis compared to the control group (6.6 +/- 2.0ng/mL, 7.6 +/- 2.8ng/mL, respectively, P>0.05). However, GAS6 levels of patients with psoriasis having a smoking history (n=11) were significantly lower than both patients with psoriasis who had no smoking history (n=29) and controls (5.5 +/- 1.7ng/mL, 6.9 +/- 1.9ng/mL, 7.6 +/- 2.8ng/mL, respectively, P<0.05). Similarly, psoriasis patients with at least one CM risk factor showed lower GAS6 levels compared to subjects without any CM risk factor (5.7 +/- 1.7ng/mL, 7.3 +/- 2.0ng/mL, P<0.01). There was no correlation between the GAS6 level, disease duration or PASI score (r=0.150, -0.150, and P=0.310, 0.398, respectively). ConclusionsThis pilot study provides the first evidence in humans for an association between low plasma GAS6 levels and conventional risk factors in psoriasis. Further large scale, prospective studies are needed to confirm these results.
dc.identifier.doi10.1111/1755-5922.12112
dc.identifier.eissn1755-5922
dc.identifier.issn1755-5914
dc.identifier.pubmed25752901
dc.identifier.urihttps://hdl.handle.net/11424/245944
dc.identifier.wosWOS:000351778100005
dc.language.isoeng
dc.publisherWILEY
dc.relation.ispartofCARDIOVASCULAR THERAPEUTICS
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAtherosclerosis
dc.subjectGrowth Arrest-Specific 6
dc.subjectPsoriasis
dc.subjectRisk Factors
dc.subjectSYSTEMIC-LUPUS-ERYTHEMATOSUS
dc.subjectK-DEPENDENT PROTEINS
dc.subjectSMOOTH-MUSCLE-CELLS
dc.subjectTAM RECEPTORS
dc.subjectCARDIOVASCULAR RISK
dc.subjectDISEASE-ACTIVITY
dc.subjectVASCULAR CALCIFICATION
dc.subjectPLASMA-CONCENTRATIONS
dc.subjectARTERIAL STIFFNESS
dc.subjectENDOTHELIAL-CELLS
dc.titleGrowth Arrest-Specific 6 and Cardiometabolic Risk Factors in Patients with Psoriasis
dc.typearticle
dspace.entity.typePublication
local.avesis.ide680af84-ee58-4b4c-af6f-ed0ece585dbd
local.import.packageSS16
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages6
oaire.citation.endPage61
oaire.citation.issue2
oaire.citation.startPage56
oaire.citation.titleCARDIOVASCULAR THERAPEUTICS
oaire.citation.volume33
relation.isAuthorOfPublicationacf48150-1ebd-4a7f-8b28-8d8f349ebeed
relation.isAuthorOfPublication.latestForDiscoveryacf48150-1ebd-4a7f-8b28-8d8f349ebeed

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Sunbul et al. - 2015 - Growth Arrest-Specific 6 and Cardiometabolic Risk .pdf
Size:
205.52 KB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs